Kaiser Permanente-backed Valeritas could raise up to $80m from the initial public offering, and will use the lion's share to market its insulin delivery device.
Valeritas, a US-based diabetes treatment developer backed by healthcare consortium Kaiser Permanente, set the range for its initial public offering between $14 and $16 a share yesterday.
The company plans to issue 5 million shares, and will raise $80m if it floats at the top of its range. Should it float at the middle of its range, Valeritas will be valued at $241m.
Founded in 2006, Valeritas’ lead product is V-Go, a small, disposable insulin delivery device to be…
